by Ferreira RAA, Junior CdOR, Martinez PDG, Koovits PJ, Soares BM, Ferreira LLG, Michelan-Duarte S, Consolin Chelucci R, Andricopulo AD, Galuppo MK, Uliana SRB, Matheeussen A, Caljon G, Maes L, Campbell S, Kratz JM, Mowbray CE, Carlos Dias L. PLOS Neglected Tropical Diseases 2021; 15(2): e0009196. doi: 10.1371/journal.pntd.0009196
Summary: The current treatment options for leishmaniasis are limited either by the length of treatment or toxic side effects. Starting from a promising hit in an in vitro phenotypic screen, hundreds of analogues were synthesized with the aim of finding a molecule capable of killing the parasite whilst causing little or no harm to the patient. The program led to several active compounds with good in vitro activity against L. infantum intracellular amastigotes, however, in vivo data showed low parasiticidal efficacy.
